Autoimmune disease

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

Frost & Sullivan Honours Outstanding Achievements in Healthcare

ROCKVILLE, Maryland and INDIANAPOLIS - Phase 3 PROTEGE ENCORE Clinical Trial Initiated MacroGenics, Inc.

Older News

LONDON - Global and European Awards recognise Healthcare Excellence The Healthcare industry's top performers were honoured at Frost & Sullivan's 'Excellence in Healthcare Awards Banquet' on Thursday 19 March at ZSL London Zoo, London.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy